Sintilimab

monoclonal antibody

Identifier: CI-DRUG-00000553
Entity page: /drug/sintilimab ↗
Edges: 449

Neighbours: 25 cancers1 genes10 trials
Drawn: 36 of 36 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Sintilimab targets …TARGETS1 of 1
→ targets	PDCD1	—	ANTAGONIST	—	1	Curated	chembl	graph →
Sintilimab investigated for …INVESTIGATED_FOR15 of 39show all (up to 200)
→ investigated for	Breast Neoplasmcancer_family	unknown

Sintilimab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 92show all (up to 200)
→ investigated in trials for	Hepatocellular Carcinomasubtype 53 trials (26 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Hepatocellular Carcinoma	53	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinomasubtype 35 trials (15 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Gastric Neoplasm 22 trials (11 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Gastric Neoplasm	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Esophageal Squamous Cell Carcinoma 14 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Esophageal Squamous Cell Carcinoma	14	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Colorectal Neoplasm 12 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Colorectal Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Gastric Neoplasmcancer_family 10 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Gastric Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 10 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Rectal Neoplasm 9 trials (7 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Rectal Neoplasm	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Nasopharyngeal Carcinomasubtype 8 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Nasopharyngeal Carcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Neoplasmcancer_family 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Esophageal Neoplasm 6 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Esophageal Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Head and Neck Squamous Cell Carcinoma 5 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Head and Neck Squamous Cell Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Intrahepatic Cholangiocarcinoma 5 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Intrahepatic Cholangiocarcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Lung Neoplasm 5 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Lung Neoplasm	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Biliary Tract Neoplasm 4 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Biliary Tract Neoplasm	4	Observed	clinicaltrials	graph →

Sintilimab investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 92show all (up to 200)

→ investigated in trials for

Hepatocellular Carcinomasubtype

53 trials (26 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Hepatocellular Carcinoma

Observed

Sintilimab studied in …STUDIED_INderived10 of 317show all (up to 200)
→ studied in	NCT06618664Phase 3 · recruiting A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (KYLIN-02) · 317 trials list this drug (156 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07840677Phase 2 · recruiting Tafolecimab Combined With Chemoimmunotherapy as Neoadjuvant Treatment for pMMR/MSS Locally Advanced Colon Cancer · 317 trials list this drug (156 active)	—	—	Malignant Colon Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07722754Phase 2 · recruiting Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial · 317 trials list this drug (156 active)	—	—	Neoplasm,Colon Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07831993Phase 2 · recruiting Sintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer · 317 trials list this drug (156 active)	—	—	Malignant Biliary Tract Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07832006Phase 2 · recruiting Irreversible Electroporation Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular Carcinoma · 317 trials list this drug (156 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07827872Phase 3 · not yet recruiting Neoadjuvant Sintilimab Plus Chemotherapy for cT2N0M0 Oral Squamous Cell Carcinoma · 317 trials list this drug (156 active)	—	—	Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Oral Cavity Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06730373Phase 2 · recruiting First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2) · 317 trials list this drug (156 active)	—	—	Malignant Gastric Neoplasm,Gastric Carcinoma,HER2-Positive Gastric Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07061535Phase 2 · recruiting Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer · 317 trials list this drug (156 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07819019Phase 2 · not yet recruiting A Phase II Study of Irinotecan Liposome Plus Fruquintinib and Sintilimab in Second-Line PD-L1-Positive Advanced Gastric Cancer · 317 trials list this drug (156 active)	—	—	Gastric Neoplasm,Malignant Gastric Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07813572Phase 3 · not yet recruiting ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular · 317 trials list this drug (156 active)	—	—	Hepatocellular Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths